Search Within

Shanu Modi

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (56)
  2. Journal Article (44)
  3. Review (4)
Groups
  1. Breast Medicine Service (104)
  2. Department of Medicine (104)
  3. GSK Faculty (104)
  4. Solid Tumor Oncology Division (104)
  5. Survivorship Research (68)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (64)

More Groups

People
  1. Sarat Chandarlapaty (49)
  2. Clifford Hudis (46)
  3. Sujata Patil (32)
  4. Larry Norton (29)
  5. Komal Jhaveri (25)
  6. Chau Dang (22)

More People

Years
  1. 2024 (8)
  2. 2023 (5)
  3. 2022 (5)
  4. 2021 (6)
  5. 2020 (9)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Cancer Research (24)
  3. Clinical Cancer Research (6)
  4. Breast Cancer Research and Treatment (5)
  5. Annals of Oncology (4)
  6. Clinical Breast Cancer (4)

More Publications

Publishers
  1. American Association for Cancer Research (31)
  2. American Society of Clinical Oncology (30)
  3. Nature Publishing Group (9)
  4. Elsevier Inc. (6)
  5. Oxford University Press (6)
  6. Springer (6)

More Publishers

Results (104)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Using the signature phenotype of inflammatory breast cancer to study dormancy and resistance to therapeutics
    Meeting Abstract

    Corben, A. D.; D'arcy, C.; Modi, S.; Chiosis, G.; Alpaugh, M. L.
    Modern Pathology (2011)

    Fulltext@MSK | Save
  • Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment
    Journal Article

    Patel, H. J.; Modi, S.; Chiosis, G.; Taldone, T.
    Expert Opinion on Drug Discovery (2011)

    Fulltext@MSK | Save
  • A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)
    Meeting Abstract

    Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Journal Article

    Morris, P. G.; Van Poznak, C.; Modi, S.; Mak, A. F.; Patil, S.; Larson, S.; Hudis, C. A.; Divgi, C.; Grewal, R. K.
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • The heat shock protein 90 chaperone complex: An evolving therapeutic target
    Journal Article

    Barginear, M. F.; Van Poznak, C.; Rosen, N.; Modi, S.; Hudis, C. A.; Budman, D. R.
    Current Cancer Drug Targets (2008)

    Fulltext@MSK | Save
  • Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
    Meeting Abstract

    Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
    Journal Article

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save